BackX.T.L. Biopharmaceuticals Overview

X.T.L. Biopharmaceuticals Net Tangible Assets

Latest net tangible assets for XTLB: $-250K.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-254000.00
104.67% YoYΔ $-5.69M vs prior year quarter

Peer average

Loading

X.T.L. Biopharmaceuticals Net Tangible Assets History

Loading

X.T.L. Biopharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

X.T.L. Biopharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

X.T.L. Biopharmaceuticals (XTLB) FAQ

As of the most recent data (December 2025), XTLB shows a net tangible assets of $-250K. That compares with $5.4M in the prior-year period — down 104.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, XTLB's net tangible assets is now $-250K (was $5.4M) — a 104.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether X.T.L. Biopharmaceuticals is outperforming or lagging.

Tracking XTLB's net tangible assets over time shows whether X.T.L. Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-250K That compares with $5.4M in the prior-year period — down 104.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has X.T.L. Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-250K) with ownership activity and broader fundamentals.

X.T.L. Biopharmaceuticals's net tangible assets is $-250K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.